| Detected | Trial | Change |
|---|---|---|
| 2026-08-08 | NCT03439735 Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6… |
date change Primary completion pushed: 2026-08-01 -> 2027-08-01 |
| 2026-08-08 | NCT03439735 Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6… |
date change Completion pushed: 2026-11-01 -> 2027-11-01 |
| 2026-08-08 | NCT07550517 PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT |
date change Primary completion pushed: 2032-07 -> 2032-08 |
| 2026-08-08 | NCT07550517 PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT |
date change Completion pushed: 2033-07 -> 2033-08 |
| 2026-08-07 | NCT05995821 Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies |
date change Primary completion pushed: 2026-08-25 -> 2028-08-25 |
| 2026-08-07 | NCT05995821 Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies |
date change Completion pushed: 2026-08-25 -> 2028-08-25 |
| 2026-08-04 | NCT05141513 Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and… |
Enrollment closed, study ongoing |
| 2026-08-04 | NCT05141513 Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and… |
Enrollment reduced: 25 -> 20 participants |
| 2026-07-29 | NCT07580339 Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR… |
date change Primary completion pushed: 2030-07 -> 2030-10 |
| 2026-07-29 | NCT07580339 Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR… |
date change Completion pushed: 2030-07 -> 2030-10 |
| 2026-07-29 | NCT05950139 Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC |
date change Primary completion pushed: 2026-07 -> 2027-07 |
| 2026-07-29 | NCT07140315 DK222 Study at Hopkins |
date change Primary completion pushed: 2027-07-01 -> 2027-09-01 |
| 2026-07-29 | NCT07140315 DK222 Study at Hopkins |
date change Completion pushed: 2027-07-01 -> 2027-09-01 |
| 2026-07-28 | NCT06411691 KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage… |
date change Primary completion pushed: 2028-03-01 -> 2029-11-01 |
| 2026-07-28 | NCT06411691 KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage… |
date change Completion pushed: 2029-07-01 -> 2030-11-01 |
| 2026-07-25 | NCT06014255 Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer |
overall status: Recruiting → Active, Not Recruiting |
| 2026-07-19 | NCT04363164 Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression |
date change Primary completion pushed: 2026-07 -> 2027-07 |
| 2026-07-19 | NCT04363164 Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression |
date change Completion pushed: 2027-07 -> 2028-07 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT06245889 | PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC | Triple Negative Breast Cancer | Recruiting |
| NCT06617923 | Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian… | Ovary Cancer | Recruiting |
| NCT04232085 | Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies… | Primary Immune Deficiency Disorder | Recruiting |
| NCT06001658 | Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary… | Billiary Track Cancer | Recruiting |
| NCT05656235 | Renal Retention in High Grade Upper Tract Urothelial Cancer | High Grade Urothelial Carcinoma | Recruiting |
| NCT06059118 | Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic… | Prostate Cancer | Recruiting |
| NCT04704505 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant… | Prostate Adenocarcinoma | Recruiting |
| NCT06616597 | Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to… | Prostate Cancer (Adenocarcinoma) | Recruiting |
| NCT04988074 | Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV… | HPV-Related Squamous Cell Carcinoma | Recruiting |
| NCT05977907 | Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck… | Head and Neck Squamous Cell Carcinoma | Recruiting |
| NCT07142551 | Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT01804634 | Reduced Intensity Haploidentical BMT for High Risk Solid Tumors | Refractory and/or Relapsed Metastatic Solid Tumors | Recruiting |
| NCT03786796 | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene… | Renal Cell Carcinoma | Recruiting |
| NCT06376669 | Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma | Renal Cell Carcinoma | Recruiting |
| NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head… | Head and Neck Cancer | Recruiting |
| NCT03521830 | Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced… | Basal Cell Carcinoma | Recruiting |
| NCT06941857 | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients… | Pancreatic Cancer | Recruiting |
| NCT06205836 | Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally… | Colorectal Cancer | Recruiting |
| NCT06922318 | The COSMYC Trial (COmbined Suppression of MYC) | Metastatic Castration-resistant Prostate Cancer | Recruiting |
| NCT05312671 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | Small Cell Neuroendocrine Carcinoma of Bladder | Recruiting |
| NCT06210854 | Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With… | HPV Infection | Recruiting |
| NCT04363164 | Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression | Castration Resistant Metastatic Prostate Cancer | Recruiting |
| NCT07281768 | Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or… | Colorectal Cancer | Recruiting |
| NCT02923180 | Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk… | Prostate Cancer | Active, Not Recruiting |
| NCT01088789 | Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer | Pancreatic Cancer | Active, Not Recruiting |